Inhibikase Therapeutics, Inc. Stock Analysis & AI Score
Inhibikase Therapeutics, Inc. (IKT) has an ST Score of 64.9 (B), driven by its Financial Strength (A+) and held back by its Growth (C). Analysts rate it Hold with a $4.83 price target (+174.4% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
AI Daily Briefing
Analysis by AIIKT Stock Price History
IKT Technical Indicators
FMPEarnings Surprises
Analyst Forecast
Revenue Mix
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Analyst Price Target
ESG Score
IKT Latest Stock News
ST Score
Inhibikase Therapeutics, Inc. (IKT) has an ST Score of 64.9 (B), driven by its Financial Strength (A+) and held back by its Growth (C). Analysts rate it Hold with a $4.83 price target (+174.4% upside).
- Strongest
- Financial StrengthA+
- Weakest
- GrowthC
All factor grades
- Financial StrengthA+
- ValuationA
- ForecastA
- MomentumB+
- ProfitabilityB-
- GrowthC
- Piotroski2/9
Press Releases
Company Contact Details
IKT stock: frequently asked questions
What is IKT's ST Score?
Inhibikase Therapeutics, Inc. (IKT) has an ST Score of 64.9 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is IKT a buy, hold, or sell?
Analysts rate IKT a Hold, with a price target of $4.83 (+174.4% vs the current price). Our ST Score grades it B (64.9/100). The ST Score is a data-driven signal, not a recommendation.
What are IKT's factor grades?
Valuation A, Profitability B-, Financial Strength A+, Momentum B+, Growth C, Forecast A.
What is IKT's valuation grade?
Inhibikase Therapeutics, Inc. (IKT) earns a valuation grade of A, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is IKT's growth grade?
Inhibikase Therapeutics, Inc. (IKT) earns a growth grade of C, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is IKT's profitability grade?
Inhibikase Therapeutics, Inc. (IKT) earns a profitability grade of B-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is IKT's financial strength grade?
Inhibikase Therapeutics, Inc. (IKT) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for IKT?
The average analyst price target for Inhibikase Therapeutics, Inc. (IKT) is $4.83 from 2 analysts, which is +174.4% versus the recent price of $1.76.
What is IKT's Piotroski score?
Inhibikase Therapeutics, Inc. (IKT) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.